Please assess the completion status of the following clinical trial:

Trial Title: Dupilumab for Severe Asthma in a Real Life Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* French patient with Severe Asthma~* Administration of dupilumab under the TUA between September 2017 and January 2018, with at least one injection~* Realization of at least one follow-up visit in the first 12 months of treatment~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).